Skip to main content
. 2023 Mar 15;14:1099921. doi: 10.3389/fimmu.2023.1099921

Table 3.

Comparison between prediction of patient survival based on TCGA dataset and review of published literature.

Gene ID Cancer type Literature reported HR for patients with high level of gene or corresponding protein in the tumors. TCGA calculated HR for patients with high expression of gene in the tumors Reference
CD44 Renal cell carcinoma high high (84)
CD44 Low grade glioma high high (85, 86)
CD44 Thyroid high low (87)
CXCR4 Breast high low (88)
CXCR4 Thyroid
(CD8 low)
high low (89)
CXCR4 Lung high low (90)
ICAM1 Breast low low (91)
ICAM1 Breast high low (92)
CDH1 Colorectal low low (93, 94)
CDH1 Low grade glioma high high (95)
CDH1 Kidney renal papillary cell carcinoma high high (96)
CDH1 Squamous cell carcinoma low low (97)
IL6R Glioblastoma high high (98)
IL6R Lung adenocarcinoma low low (99, 100)
IL6R Kidney renal clear cell carcinoma high low (101, 102)
NOTCH1 Kidney renal clear cell carcinoma high low (103, 104)
NOTCH1 Low grade glioma high low (105, 106)
TGFBR2 Lung adenocarcinoma low low (107, 108)
TGFBR2 Lung squamous cell carcinoma low high (107, 108)
TGFBR2 Breast cancer low high (109, 110)
TGFBR2 Breast cancer high high (111)
EPCAM Breast cancer high low (112)
EPCAM Low grade glioma high low (113)
EPCAM Kidney renal clear cell carcinoma low low (114)
EPCAM Kidney renal papillary cell carcinoma low low (114)
VCAM1 Kidney renal clear cell carcinoma low low (115, 116)